Title :

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplants for patients with Hodgkin lymphoma: a comparative study of the LWP EBMT.: GVHD prophylaxis for patients with Hodgkin lymphoma.

Author(s) :

Montoro, Juan [Auteur]
Universidad Catolica de Valencia San Vicente Mártir = Saint Vincent the Martyr Catholic University of Valencia [UCV]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Boumendil, Ariane [Auteur]
Finel, Hervé [Auteur]
Bramanti, Stefania [Auteur]
Istituto Clinico Humanitas [Milan] [IRCCS Milan]
Castagna, Luca [Auteur]
Istituto Clinico Humanitas [Milan] [IRCCS Milan]
Blaise, Didier [Auteur]
Aix Marseille Université [AMU]
Dominietto, Alida [Auteur]
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Kulagin, Aleksandr [Auteur]
Pavlov First Saint Petersburg State Medical University [St. Petersburg]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Tbakhi, Abdelghani [Auteur]
Solano, Carlos [Auteur]
Universitat de València = University of Valencia [UV]
Giebel, Sebastian [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Gulbas, Zafer [Auteur]
Anadolu [Turkey]
López Corral, Lucia [Auteur]
Universidad de Salamanca [España] = University of Salamanca [Spain]
Pérez-Simón, José A. [Auteur]
Hospital Universitario Virgen del Rocío [Sevilla]
Díez Martín, José Luis [Auteur]
Hospital General Universitario "Gregorio Marañón" [Madrid]
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Farina, Lucia [Auteur]
IRCCS Istituto Nazionale dei Tumori [Milano]
Koc, Yener [Auteur]
Socié, Gerard [Auteur]
Arat, Mutlu [Auteur]
Jurado, Manuel [Auteur]
Universidad de Granada = University of Granada [UGR]
Bermudez, Arancha [Auteur]
Hospital Universitario Marqués de Valdecilla [Santander]
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Villalba, Marta [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Ciceri, Fabio [Auteur]
IRCCS Ospedale San Raffaele [Milan, Italy]
Rodriguez, Carmen Martinez [Auteur]
Clinic Barcelona Hospital Universitari
Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Sureda, Anna [Auteur]
Universitat de Barcelona [UB]
Glass, Bertram [Auteur]
Asklepios Klinikum Harburg [Hamburg, Germany] [AKH]

Journal title :

Transplantation and Cellular Therapy

Abbreviated title :

Transplant Cell Ther

Publication date :

2023-12-05

ISSN :

2666-6367

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Post-transplantation cyclophosphamide (PTCy) has emerged as a promising approach for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is a lack ...
Show more >Post-transplantation cyclophosphamide (PTCy) has emerged as a promising approach for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is a lack of studies examining the impact of this GVHD prophylaxis when different donor types are used in patients with Hodgkin lymphoma (HL). This study compared the outcomes of patients with HL undergoing HSCT from HLA-matched donors, including matched sibling donors (MSDs) and matched unrelated donors (MUDs), and haploidentical donors, using PTCy as the GVHD prophylaxis approach in all cohorts. We retrospectively compared outcomes of allo-HSCT from 166 HLA-matched donors (96 sibling and 70 unrelated donors) and 694 haploidentical donors using PTCy-based GVHD prophylaxis in patients with HL registered in the European Society for Blood and Marrow Transplantation database from 2010 to 2020. Compared to HLA-matched HSCT, haploidentical donor HSCT was associated with a significantly lower rate of platelet engraftment (86% versus 94%; P < .001) and a higher rate of grade II-IV acute GVHD (34% versus 24%; P = .01). The 2-year cumulative incidence of nonrelapse mortality (NRM) was significantly lower in the HLA-matched cohort compared to the haploidentical cohort (10% versus 18%; P = .02), resulting in a higher overall survival (OS) rate (82% versus 70%; P = .002). There were no significant differences between the 2 cohorts in terms of relapse, progression-free survival, or GVHD-free relapse-free survival. In multivariable analysis, haploidentical HSCT was associated with an increased risk of grade II-IV acute GVHD and NRM and worse OS compared to HLA-matched HSCT. Our findings suggest that in the context of PTCy-based GVHD prophylaxis, transplantation from HLA-matched donors appears to be a more favorable option compared to haploidentical HSCT.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-02-06T22:16:31Z
2024-03-19T13:04:14Z